金融界9月26日消息，中国中药在2024年6月30日止的六个月，其他收入约为人民币79,597,000元，这比去年同期的人民币83,130,000元减少了4.2%。主要原因是报告期内公司获得的利息收入约为人民币16,320,000元，相比去年同期的人民币31,301,000元减少了47.9%。此外，其他损失约为人民币64,768,000元，远高于2023年同期的人民币14,004,000元。销售及分销成本约为人民币2,752,658,000元，比去年同期减少了13.6%，主要是销售结构变化导致中药配方颗粒收入同比下降、相关销售费用减少。期内行政支出约为人民币512,150,000元，比去年同期上涨10.2%，主因是生产性企业经营规模扩大、管理人员数量和薪酬增长。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.